Journal of Neurology

, Volume 248, Supplement 1, pp I3–I10

Pharmacology and immunology of botulinum toxin serotypes

  • K. R. Aoki

DOI: 10.1007/PL00007816

Cite this article as:
Aoki, K. J Neurol (2001) 248: I3. doi:10.1007/PL00007816

Abstract

Botulinum toxin preparations can provide patients with a therapeutic modality that may improve both their medical condition and quality of life. The mechanism of action of the various botulinum toxin preparations and serotypes is similar: they all block neurotransmitter release. The majority of clinical conditions treated are based upon the targeted temporary chemodenervation of the selected organ. The antinociceptive effects of botulinum toxin type A (BTX-A), based on preclinical studies and clinical experiences in treating movement disorders and other painful conditions, will also be reviewed to illustrate how this compound may act as it alleviates the discomfort associated with various conditions. Chronic therapies with preparations with the lowest amount of neurotoxin protein provide the best chance for long-term therapy by minimizing the potential of the patient to form neutralizing antibodies. Differences in formulations or serotypes impart unique efficacy and safety profiles and thus does not support a simple dose ratio conversion between products.

Key words Botox®Dysport®Myobloc™ChemodenervationAnalgesiaSafety marginBotulinum toxin type ABotulinum toxin type B

Copyright information

© Steinkopff Verlag 2001

Authors and Affiliations

  • K. R. Aoki
    • 1
  1. 1.Allergan, Inc., Irvine, CA 92623, USAUS